Table 1. Demographics and clinical characteristics of study patients.
| Patients (N = 130) | |
|---|---|
| Mean age at visit, years | 50.28 ± 11.70 |
| Mean age at onset, years | 44.17 ± 9.75 |
| Disease duration, years | 6.12 ± 6.34 |
| Male/Female | 4/126 |
| Phakia/Pseudophakia | 121/9 |
| BCVA, logMAR | 0.03 ± 0.08 |
| SE refractive error, diopter | -0.68 ± 1.84 |
| IOP, mmHg | 14.26 ± 3.30 |
| Humphrey visual field | |
| MD, dB | -0.97 ± 1.89 |
| PSD, dB | 1.84 ± 1.09 |
| VFI, % | 97.31 ± 2.92 |
| Laboratory test | |
| WBC, 103/μl | 5.60 ± 2.23 |
| Lymphocyte, 103/μl | 1.82 ± 0.64 |
| ESR, mm/hr | 34.84± 23.49 |
| CRP, mg/dL | 0.28 ± 1.11 |
| Immunoglobulin, mg/dl | |
| Ig G, g/L | 18.99 ± 6.08 |
| Ig M, g/L | 1.50 ± 1.19 |
| Ig A, g/L | 3.30 ± 1.20 |
| Autoimmune lab | |
| ANA positive, n (%) | 127 (97.7) |
| Anti-SSA positive, n (%) | 116 (89.2) |
| Anti-SSA level, U/mL | 154.18 ± 74.12 |
| Anti-SSB positive, n (%) | 47 (36.2) |
| Anti-SSB level, U/mL | 44.07 ± 69.10 |
| RF positive (%) | 68 (52.3) |
| RF, IU/mL | 47.20 ± 68.14 |
| LFS, n (%) | 0.92 ± 1.19 |
| Score <1 | 73 (56.2) |
| Score ≥ 1 | 57 (43.8) |
| OCT, n (%) | |
| Abnormally reduced pRNFL | 22 (16.9) |
| Abnormally reduced mGCIPL | 33 (25.4) |
BCVA, best-corrected visual acuity; LogMAR, logarithm of the minimal angle of resolution; IOP, intraocular pressure; SE, spherical equivalent; MD, mean deviation; PSD, pattern standard deviation; VFI, visual field index; WBC, white blood cell; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; D, diopters; Ig, Immunoglobulin; ANA, antinuclear antibody; Anti-SSA/SSB, anti-Sjögren syndrome A and/or B antibodies; RF, rheumatoid factor; LFS, lymphocytic focus score; OCT, optical coherence tomography; pRNFL, peripapillary retinal nerve fiber layer; mGCIPL, macular ganglion cell-inner plexiform layer.